1986
The effect of combined modality therapy on local control and survival
DeVita V, Lippman M, Hubbard S, Ihde D, Rosenberg S. The effect of combined modality therapy on local control and survival. International Journal Of Radiation Oncology • Biology • Physics 1986, 12: 487-501. PMID: 3009367, DOI: 10.1016/0360-3016(86)90056-8.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsAnus NeoplasmsBreast NeoplasmsCarcinoma, Small CellClinical Trials as TopicCombined Modality TherapyFemaleHumansKidney NeoplasmsLung NeoplasmsLymphomaNeoplasm MetastasisNeoplasm Recurrence, LocalNeoplasmsPrognosisSarcomaSoft Tissue NeoplasmsWilms TumorConceptsLocal controlSystemic treatmentTumor typesPresence of micrometastasesEffective systemic therapyTumor cell numberLocal control measuresModality therapySystemic therapyCommon cancerMetastatic cancerLESS surgeryRadiation therapyTherapeutic programMetastatic processMicrometastasesTherapySurvivalSystemic componentCell numberTumorsMetastasis genesCancerSubstantial numberInverse relationship
1984
Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience.
Tester W, Kinsella T, Waller B, Makuch R, Kelley P, Glatstein E, DeVita V. Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience. Journal Of Clinical Oncology 1984, 2: 762-9. PMID: 6547479, DOI: 10.1200/jco.1984.2.7.762.Peer-Reviewed Original ResearchConceptsSecond malignant neoplasmsHodgkin's diseaseMalignant neoplasmsSolid tumorsNational Cancer Institute ExperienceChronic myeloid leukemiaCases of sarcomaRisk of leukemiaUntreated patientsPatient ageHodgkin's lymphomaMedical recordsInstitute experienceMyeloid leukemiaSimilar riskAge 40Treatment groupsPatientsGreater riskLeukemiaTen yearsDiseaseTumorsLymphomaPositive association25 THERAPEUTIC RESEARCH IN THE NATIONAL CANCER INSTITUTE
DeVita V, Goidin A. 25 THERAPEUTIC RESEARCH IN THE NATIONAL CANCER INSTITUTE. 1984, 499-526. DOI: 10.1016/b978-0-12-667980-9.50032-4.Peer-Reviewed Original ResearchCombination of drugsTypes of tumorsNational Cancer InstituteGroup of diseasesDosage scheduleCancer therapistClinical oncologistsCancer InstituteExperimental animalsBeneficial effectsTherapeutic researchTumorsDrugsTreatmentSignificant numberField of medicineRemissionChemotherapyPatientsSurgeryOncologistsRadiotherapyCancerDiseasePhysicians
1981
Current results of the screening program at the division of cancer treatment, national cancer institute
Goldin A, Venditti J, Macdonald J, Muggia F, Henney J, Devita V. Current results of the screening program at the division of cancer treatment, national cancer institute. European Journal Of Cancer 1981, 17: 129-142. PMID: 6894902, DOI: 10.1016/0014-2964(81)90027-x.Peer-Reviewed Original ResearchConceptsNational Cancer InstituteScreening programCancer treatmentClinical trialsCancer InstituteHuman tumorsProspective screening programInadequate clinical trialsCategories of drugsActivity of drugsRenal capsuleClinical testingPanel testingScreening panelNew synthetic compoundsClinical interestNew drugsDrugsSubcutaneous modelTreatmentTumorsAntitumor agentsTrialsPotential usefulnessDefinitive answer
1978
Clinical Relevance of the Histopathological Subclassification of Diffuse Histiocytic Lymphoma
Strauchen J, Young R, Devita V, Anderson T, Fantone J, Berard C. Clinical Relevance of the Histopathological Subclassification of Diffuse Histiocytic Lymphoma. New England Journal Of Medicine 1978, 299: 1382-1387. PMID: 362206, DOI: 10.1056/nejm197812212992503.Peer-Reviewed Original ResearchConceptsComplete response rateDiffuse histiocytic lymphomaHistopathological subclassificationExcellent prognosisIntermediate prognosisBetter prognosisPoor prognosisHistiocytic lymphomaMorphologic subclassificationHistopathological categoriesHeterogeneous diseaseClinical relevancePrognosisResponse rateMorphologic featuresLymphomaChemotherapyPatientsTumorsSubclassificationSurvivalDifferencesDisease
1973
Streptozotocin for Malignant Insulinomas and Carcinoid Tumor: Report of Eight Cases and Review of the Literature
Schein P, Kahn R, Gorden P, Wells S, DeVita V. Streptozotocin for Malignant Insulinomas and Carcinoid Tumor: Report of Eight Cases and Review of the Literature. JAMA Internal Medicine 1973, 132: 555-561. DOI: 10.1001/archinte.1973.03650100069013.Peer-Reviewed Original ResearchMalignant insulinomaBone marrow depressionDrug dose levelsPeak serum concentrationComplete remissionMarrow depressionMetastatic insulinomaObjective responseCarcinoid tumorsMalignant carcinoidSerum concentrationsInfusion rateLow doseStreptozotocinDose levelsInjection sitePatientsInsulinomaLimited responseRemissionCarcinoidsResponseChemotherapyPainTumorsLiver‐spleen scan in hodgkin's disease
Milder M, Larson S, Bagley C, Devita V, Johnson R, Johnston G. Liver‐spleen scan in hodgkin's disease. Cancer 1973, 31: 826-834. PMID: 4706049, DOI: 10.1002/1097-0142(197304)31:4<826::aid-cncr2820310410>3.0.co;2-m.Peer-Reviewed Original ResearchConceptsLiver-spleen scanLiver involvementHodgkin's diseaseFilling defectPhysical examinationTumor involvementLiver biopsyPathologic findingsHepatic lobeLiver scanSplenic tumorAdvanced stageReliable signDiseaseSpleenTumorsScansLymphangiogramPatientsLiverInvolvementExaminationSplenomegalyBiopsyFindings
1972
Nonlymphomatous Malignant Tumors Complicating Hodgkin's Disease — Possible Association with Intensive Therapy
Arseneau J, Sponzo R, Levin D, Schnipper L, Bonner H, Young R, Canellos G, Johnson R, DeVita V. Nonlymphomatous Malignant Tumors Complicating Hodgkin's Disease — Possible Association with Intensive Therapy. New England Journal Of Medicine 1972, 287: 1119-1122. PMID: 5082192, DOI: 10.1056/nejm197211302872204.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic AgentsCarcinoma, Squamous CellCyclophosphamideDrug-Related Side Effects and Adverse ReactionsFemaleFibrosarcomaFollow-Up StudiesHead and Neck NeoplasmsHodgkin DiseaseHumansMaleMiddle AgedNeoplasm MetastasisNeoplasmsNeoplasms, Radiation-InducedNitrogen Mustard CompoundsPrednisoneProcarbazineRadiotherapyRemission, SpontaneousTime FactorsVincristineConceptsHodgkin's diseaseMalignant tumorsIntensive radiotherapyIntensive chemotherapyBiopsy-proven malignant tumorsTime of diagnosisSecond malignant tumorsRisk of developmentBasis of treatmentBasis of ageIntensive therapyCase recordsChemotherapyDiseasePatientsRadiotherapyTumorsGreater increaseSubgroupsRiskTherapyIncidenceDiagnosisClinical trials with 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) given intravenously.
Bagley C, Canellos G, Young R, Gallelli J, Devita V. Clinical trials with 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) given intravenously. Cancer Chemotherapy Reports 1972, 56: 387-91. PMID: 19051499.Peer-Reviewed Original ResearchConceptsClinical trialsDose-limiting toxic effectPhase II trialBone marrow toxicityConsecutive daily injectionsTime of onsetDegree of severitySevere nauseaII trialObjective responseDaily injectionsMarrow toxicityPatientsTrialsToxic effectsToxicityNauseaVomitingPainLymphomaMelanomaTumorsLymphosarcomaAdministrationDose
1971
Treatment of Advanced Hodgkin's Disease with [1,3 Bis (2-Chloroethyl)-L-Nitrosourea] BCNU
Young R, DeVita V, Serpick A, Canellos G. Treatment of Advanced Hodgkin's Disease with [1,3 Bis (2-Chloroethyl)-L-Nitrosourea] BCNU. New England Journal Of Medicine 1971, 285: 475-479. PMID: 5558887, DOI: 10.1056/nejm197108262850902.Peer-Reviewed Original Research
1970
CELL CYCLE CHARACTERISTICS OF HUMAN SOLID TUMORS IN VIVO
Young R, DeVita V. CELL CYCLE CHARACTERISTICS OF HUMAN SOLID TUMORS IN VIVO. Cell Proliferation 1970, 3: 285-290. PMID: 5523056, DOI: 10.1111/j.1365-2184.1970.tb00273.x.Peer-Reviewed Original Research